oncopatОнкопатологияONCOPATHOLOGY2618-70193034-353410.17650/2618-7019-2023-6-1-2-19-25oncopat-73Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСистема стандартизации цитологических заключений Всемирной организации здравоохранения припатологии панкреатобилиарной зоныThe World Health Organization Reporting System for Pancreaticobiliary CytopathologyПрилучныйС. В.PriluchnyS. V.

Сергей Викторович Прилучный 121359 Москва, ул. Маршала Тимошенко, 15

Sergey Viktorovich Priluchny 15 Marshala Timoshenko St., Moscow 121359

sergey.priluchny@bk.ruФурминскаяЕ. Ю.FurminskayaE. Yu.

121359 Москва, ул. Маршала Тимошенко, 15

15 Marshala Timoshenko St., Moscow 121359

ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской ФедерацииРоссияCentral Clinical Hospital with Polyclinic, Administration of the President of the Russian FederationRussian Federation20233009202661-21925Copyright © Прилучный С.В., Фурминская Е.Ю., 20262026Прилучный С.В., Фурминская Е.Ю.Priluchny S.V., Furminskaya E.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://oncopat.elpub.ru/jour/article/view/73

Международная академия цитологии (The International Academy of Cytology, IAC), Международное агентство по изучению рака (The International Agency for Research on Cancer, IARC), Объединенный редакционный совет Всемирной организации здравоохранения (World Health Organization Joint Editorial Board) разработали систему стандартных цитологических заключений для панкреатобилиарной зоны в соответствии с классификацией опухолей пищеварительной системы 5-го издания. Система включает в себя 7 категорий: «Недостаточный/неадекватный/недиагностический материал», «Доброкачественный процесс», «Материал с признаками атипии», «Панкреатобилиарное новообразование с низким риском злокачественности», «Панкреатобилиарное новообразование с высоким риском злокачественности», «Подозрение на злокачественную опухоль» и «Злокачественная опухоль». Для каждой категории разработаны четкие диагностические критерии, приведены предполагаемые риски злокачественного новообразования и рекомендованная тактика ведения пациента. Система разработана для унификации формулировок заключений и облегчения коммуникации морфологов, врачей функциональной диагностики и врачей-клиницистов.

The International Academy of Cytology (IAC), the International Agency for Research on Cancer (IARC), and the World Health Organization Joint Editorial Board have developed an international approach to standardized reporting of pancreaticobiliary cytopathology with the same methodology used for the WHO Classification for Gastrointestinal Tumors, 5th edition. The reporting system includes 7 categories: “Insufficient/inadequate/nondiagnostic”, “Benign/negative for malignancy”, “Atypical”, “Pancreatic neoplasm of low risk/low-grade”, “Pancreatic neoplasm of high risk/high-grade”, “Suspicious for malignancy”, and “Positive for malignancy”. Each diagnostic category has clear diagnostic criteria, estimated risk of malignancy, and clinical management options. The system has been developed to unify terminology for reports and facilitate communication between morphologists, functional diagnostics specialists, and clinicians.

цитологическое исследованиеподжелудочная железасистема стандартизации цитологических заключений Всемирной организации здравоохранения при патологии панкреатобилиарной зоныcytological examinationpancreasthe World Health Organization Reporting System for Pancreaticobiliary CytopathologyРабота выполнена без спонсорской поддержкиThe work was performed without external fundingReferencesPitman M., Centeno B., Reid M., et al. The World Health Organization Reporting System for Pancreaticobiliary Cytopathology. Acta Cytologica. 2022:1–17. DOI: 10.1159/000527912.Pitman M., Centeno B., Reid M., et al. The World Health Organization Reporting System for Pancreaticobiliary Cytopathology. Acta Cytologica. 2022:1–17. DOI: 10.1159/000527912.International Academy of Cytology – International Agency for Research on Cancer – World Health Organization Joint Editorial Board. WHO Reporting System for Pancreaticobiliary Cytopathology. Lyon, France: International Agency for Research on Cancer; 2022. Available at: https://tumourclassification.iarc.who.int/chapters/50.International Academy of Cytology – International Agency for Research on Cancer – World Health Organization Joint Editorial Board. WHO Reporting System for Pancreaticobiliary Cytopathology. Lyon, France: International Agency for Research on Cancer; 2022. Available at: https://tumourclassification.iarc.who.int/chapters/50.Smith A.L., Abdul-Karim F.W., Goyal A. Cytologic categorization of pancreatic neoplastic mucinous cysts with an assessment of the risk of malignancy: a retrospective study based on the Papanicolaou Society of Cytopathology guidelines. Cancer Cytopathol. 2016;124(4):285–293. DOI: 10.1002/cncy.21657.Smith A.L., Abdul-Karim F.W., Goyal A. Cytologic categorization of pancreatic neoplastic mucinous cysts with an assessment of the risk of malignancy: a retrospective study based on the Papanicolaou Society of Cytopathology guidelines. Cancer Cytopathol. 2016;124(4):285–293. DOI: 10.1002/cncy.21657.Hoda R.S., Finer E.B., Arpin R.N., et al. Risk of malignancy in the categories of the Papanicolaou Society of Cytopathology system for reporting pancreaticobiliary cytology. J Am Soc Cytopathol. 2019;8(3):120–127. DOI: 10.1016/j.jasc.2019.01.002.Hoda R.S., Finer E.B., Arpin R.N., et al. Risk of malignancy in the categories of the Papanicolaou Society of Cytopathology system for reporting pancreaticobiliary cytology. J Am Soc Cytopathol. 2019;8(3):120–127. DOI: 10.1016/j.jasc.2019.01.002.Sung S., Del Portillo A., Gonda T.A., et al. Update on risk stratification in the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology categories: 3-year, prospective, single-institution experience. Cancer Cytopathol. 2020;128(1):29–35. DOI: 10.1002/cncy.22199.Sung S., Del Portillo A., Gonda T.A., et al. Update on risk stratification in the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology categories: 3-year, prospective, single-institution experience. Cancer Cytopathol. 2020;128(1):29–35. DOI: 10.1002/cncy.22199.Hoda R.S., Arpin R.N., Rosenbaum M.W., Pitman M.B. Risk of malignancy associated with diagnostic categories of the proposed World Health Organization International System for Reporting Pancreaticobiliary Cytopathology. Cancer Cytopathol. 2022;130(3):195–201. DOI: 10.1002/cncy.22514.Hoda R.S., Arpin R.N., Rosenbaum M.W., Pitman M.B. Risk of malignancy associated with diagnostic categories of the proposed World Health Organization International System for Reporting Pancreaticobiliary Cytopathology. Cancer Cytopathol. 2022;130(3):195–201. DOI: 10.1002/cncy.22514.Vandervoort J., Soetikno R.M., Montes H., et al. Accuracy and complication rate of brush cytology from bile duct versus pancreatic duct. Gastrointest Endosc. 1999;49(3 Pt 1):322–327. DOI: 10.1016/S0016-5107(99)70008-8.Vandervoort J., Soetikno R.M., Montes H., et al. Accuracy and complication rate of brush cytology from bile duct versus pancreatic duct. Gastrointest Endosc. 1999;49(3 Pt 1):322–327. DOI: 10.1016/S0016-5107(99)70008-8.Chadwick B.E., Layfield L.J., Witt B.L., et al. Significance of atypia in pancreatic and bile duct brushings: follow-up analysis of the categories atypical and suspicious for malignancy. Diagn Cytopathol. 2014;42(4):285–291. DOI: 10.1002/dc.23035.Chadwick B.E., Layfield L.J., Witt B.L., et al. Significance of atypia in pancreatic and bile duct brushings: follow-up analysis of the categories atypical and suspicious for malignancy. Diagn Cytopathol. 2014;42(4):285–291. DOI: 10.1002/dc.23035.Dudley J.C., Zheng Z., McDonald T., et al. Next-generation sequencing and fluorescence in situ hybridization have comparable performance characteristics in the analysis of pancreaticobiliary brushings for malignancy. J Mol Diagn. 2016;18(1):124–130. DOI: 10.1016/j.jmoldx.2015.08.002.Dudley J.C., Zheng Z., McDonald T., et al. Next-generation sequencing and fluorescence in situ hybridization have comparable performance characteristics in the analysis of pancreaticobiliary brushings for malignancy. J Mol Diagn. 2016;18(1):124–130. DOI: 10.1016/j.jmoldx.2015.08.002.Yeo M.K., Kim K.H., Lee Y.M., et al. The usefulness of adding p53 immunocytochemistry to bile drainage cytology for the diagnosis of malignant biliary strictures. Diagn Cytopathol. 2017;45(7):592–597. DOI: 10.1002/dc.23729.Yeo M.K., Kim K.H., Lee Y.M., et al. The usefulness of adding p53 immunocytochemistry to bile drainage cytology for the diagnosis of malignant biliary strictures. Diagn Cytopathol. 2017;45(7):592–597. DOI: 10.1002/dc.23729.Poller D.N., Schmitt F. Should uncertainty concerning the risk of malignancy be included in diagnostic (nongynecologic) cytopathology reports? Cancer Cytopathol. 2021;129(1):16–21. DOI: 10.1002/cncy.22322.Poller D.N., Schmitt F. Should uncertainty concerning the risk of malignancy be included in diagnostic (nongynecologic) cytopathology reports? Cancer Cytopathol. 2021;129(1):16–21. DOI: 10.1002/cncy.22322.Layfield L.J., Zhang T., Esebua M. Diagnostic sensitivity and risk of malignancy for bile duct brushings categorized by the Papanicolaou Society of Cytopathology System for reporting pancreaticobiliary cytopathology. Diagn Cytopathol. 2022;50(1):24–27. DOI: 10.1002/dc.24901.Layfield L.J., Zhang T., Esebua M. Diagnostic sensitivity and risk of malignancy for bile duct brushings categorized by the Papanicolaou Society of Cytopathology System for reporting pancreaticobiliary cytopathology. Diagn Cytopathol. 2022;50(1):24–27. DOI: 10.1002/dc.24901.Nikas I.P., Proctor T., Seide S., et al. Diagnostic performance of pancreatic cytology with the Papanicolaou Society of Cytopathology System: a systematic review, before shifting into the upcoming WHO International System. Int J Mol Sci. 2022;23(3):1650. DOI: 10.3390/ijms23031650.Nikas I.P., Proctor T., Seide S., et al. Diagnostic performance of pancreatic cytology with the Papanicolaou Society of Cytopathology System: a systematic review, before shifting into the upcoming WHO International System. Int J Mol Sci. 2022;23(3):1650. DOI: 10.3390/ijms23031650.Pitman M.B., Centeno B.A., Ali S.Z., et al. Papanicolaou Society of Cytopathology. Standardized terminology and nomenclature for pancreatobiliary cytology: the Papanicolaou Society of Cytopathology guidelines. Diagn Cytopathol. 2014;42(4):338–350. DOI: 10.1002/dc.23092.Pitman M.B., Centeno B.A., Ali S.Z., et al. Papanicolaou Society of Cytopathology. Standardized terminology and nomenclature for pancreatobiliary cytology: the Papanicolaou Society of Cytopathology guidelines. Diagn Cytopathol. 2014;42(4):338–350. DOI: 10.1002/dc.23092.Pitman M.B., Centeno B.A., Genevay M., et al. Grading epithelial atypia in endoscopic ultrasound-guided fine-needle aspiration of intraductal papillary mucinous neoplasms: an international interobserver concordance study. Cancer Cytopathol. 2013;121(12):729–736. DOI: 10.1002/cncy.21334.Pitman M.B., Centeno B.A., Genevay M., et al. Grading epithelial atypia in endoscopic ultrasound-guided fine-needle aspiration of intraductal papillary mucinous neoplasms: an international interobserver concordance study. Cancer Cytopathol. 2013;121(12):729–736. DOI: 10.1002/cncy.21334.Hoda R.S., Finer E.B., Arpin R.N., et al. Risk of malignancy in the categories of the Papanicolaou Society of Cytopathology system for reporting pancreaticobiliary cytology. J Am Soc Cytopathol. 2019;8(3):120–127. DOI: 10.1016/j.jasc.2019.01.002.Hoda R.S., Finer E.B., Arpin R.N., et al. Risk of malignancy in the categories of the Papanicolaou Society of Cytopathology system for reporting pancreaticobiliary cytology. J Am Soc Cytopathol. 2019;8(3):120–127. DOI: 10.1016/j.jasc.2019.01.002.Sung S., Del Portillo A., Gonda T.A., et al. Update on risk stratification in the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology categories: 3-year, prospective, single-institution experience. Cancer Cytopathol. 2020;128(1):29–35. DOI: 10.1002/cncy.22199.Sung S., Del Portillo A., Gonda T.A., et al. Update on risk stratification in the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology categories: 3-year, prospective, single-institution experience. Cancer Cytopathol. 2020;128(1):29–35. DOI: 10.1002/cncy.22199.Brugge W.R., Lewandrowski K., Lee-Lewandrowski E., et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126(5):1330–1336. DOI: 10.1053/j.gastro.2004.02.013.Brugge W.R., Lewandrowski K., Lee-Lewandrowski E., et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126(5):1330–1336. DOI: 10.1053/j.gastro.2004.02.013.Cizginer S., Turner B.G., Bilge A.R., et al. Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas. 2011;40(7):1024–1028. DOI: 10.1097/MPA.0b013e31821bd62f. Erratum in: Pancreas. 2013;42(4):728.Cizginer S., Turner B.G., Bilge A.R., et al. Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas. 2011;40(7):1024–1028. DOI: 10.1097/MPA.0b013e31821bd62f. Erratum in: Pancreas. 2013;42(4):728.Cizginer S., Turner B.G., Bilge A.R., et al. Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas. 2011;40(7):1024–1028. DOI: 10.1097/MPA.0b013e31821bd62f. Erratum in: Pancreas. 2013;42(4):728.Cizginer S., Turner B.G., Bilge A.R., et al. Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas. 2011;40(7):1024–1028. DOI: 10.1097/MPA.0b013e31821bd62f. Erratum in: Pancreas. 2013;42(4):728.European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67(5):789–804. DOI: 10.1136/gutjnl-2018-316027.European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67(5):789–804. DOI: 10.1136/gutjnl-2018-316027.Elta G.H., Enestvedt B.K., Sauer B.G., Lennon A.M. ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol. 2018;113(4):464–479. DOI: 10.1038/ajg.2018.14.Elta G.H., Enestvedt B.K., Sauer B.G., Lennon A.M. ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol. 2018;113(4):464–479. DOI: 10.1038/ajg.2018.14.Megibow A.J., Baker M.E., Morgan D.E., et al. Management of Incidental Pancreatic Cysts: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2017;14(7):911–923. DOI: 10.1016/j.jacr.2017.03.010.Megibow A.J., Baker M.E., Morgan D.E., et al. Management of Incidental Pancreatic Cysts: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2017;14(7):911–923. DOI: 10.1016/j.jacr.2017.03.010.Tanaka M., Fernández-del Castillo C., Adsay V., et al. International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–197. DOI: 10.1016/j.pan.2012.04.004.Tanaka M., Fernández-del Castillo C., Adsay V., et al. International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–197. DOI: 10.1016/j.pan.2012.04.004.Tanaka M., Fernández-Del Castillo C., Kamisawa T., et al. Revisions of International Consensus Fukuoka Guidelines for the Management of IPMN of the Pancreas. Pancreatology. 2017;17(5):738–753. DOI: 10.1016/j.pan.2017.07.007.Tanaka M., Fernández-Del Castillo C., Kamisawa T., et al. Revisions of International Consensus Fukuoka Guidelines for the Management of IPMN of the Pancreas. Pancreatology. 2017;17(5):738–753. DOI: 10.1016/j.pan.2017.07.007.European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67(5):789–804. DOI: 10.1136/gutjnl-2018-316027.European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67(5):789–804. DOI: 10.1136/gutjnl-2018-316027.Vege S.S., Ziring B., Jain R., et al. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Asymptomatic Neoplastic Pancreatic Cysts. Gastroenterology. 2015;148(4):819–822. DOI: 10.1053/j.gastro.2015.01.015.Vege S.S., Ziring B., Jain R., et al. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Asymptomatic Neoplastic Pancreatic Cysts. Gastroenterology. 2015;148(4):819–822. DOI: 10.1053/j.gastro.2015.01.015.

The authors declare that there are no conflicts of interest present.